PMID- 25212256
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141206
LR  - 20211021
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 4
IP  - 2
DP  - 2014 Dec
TI  - Efficacy and safety of nadifloxacin for bacterial skin infections: results from 
      clinical and post-marketing studies.
PG  - 233-48
LID - 10.1007/s13555-014-0062-1 [doi]
AB  - INTRODUCTION: Skin and soft tissue infections involve microbial invasion of the 
      skin and underlying soft tissues and are estimated to affect 7-10% of 
      hospitalized patients worldwide. Nadifloxacin, a topical fluoroquinolone, has 
      been shown to be effective against aerobic Gram-negative, Gram-positive 
      (including MRSA and coagulase-negative staphylococci), and anaerobic bacteria. 
      However, there is paucity of data comparing efficacy and safety of 1% 
      nadifloxacin with other anti-bacterials for skin infections in Indian patients. 
      METHODS: This article presents the results of one post-marketing surveillance 
      (PMS) and three randomized, open, non-blinded, multi-centric clinical studies 
      that compared nadifloxacin with mupirocin and framycetin, and nadifloxacin with 
      fusidic acid. Patients in India, aged from 1 to 65 years old, suffering from mild 
      to moderate bacterial skin infections including impetigo, secondarily infected 
      wounds, folliculitis, infected atopic dermatitis, and furunculosis were randomly 
      allocated to three treatment groups within the studies. Efficacy was assessed by 
      the evaluation of symptoms of erythema, exudation, swelling, pruritus, crusting, 
      pain and tenderness in all the studies. RESULTS: A total of 272 subjects were 
      enrolled in the study and subjects were randomly assigned to one of the three 
      treatment groups; 92 in the nadifloxacin group, 90 in the mupirocin group, and 90 
      in the framycetin group. A significant reduction in the mean scores for bacterial 
      infection symptoms in the nadifloxacin groups was observed when compared to 
      mupirocin, framycetin and fusidic acid groups. Both physician and patients rated 
      nadifloxacin as excellent (complete remission of symptoms) on a 4-point scale in 
      the studies. No adverse events (AEs) were reported in the clinical studies. In 
      the PMS, only two patients (of 329, 0.6%) reported AEs including burning and 
      itching, one in each patient that had resolved at the time of reporting. 
      CONCLUSION: Nadifloxacin, a fluoroquinolone, is a new alternative topical agent 
      in the treatment of bacterial skin infection with minimal AEs.
FAU - Narayanan, Varsha
AU  - Narayanan V
AD  - Wockhardt Ltd., Wockhardt Towers, Bandra Kurla Complex, Mumbai, 400051, India.
FAU - Motlekar, Salman
AU  - Motlekar S
FAU - Kadhe, Ganesh
AU  - Kadhe G
FAU - Bhagat, Seema
AU  - Bhagat S
LA  - eng
PT  - Journal Article
DEP - 20140912
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC4257952
EDAT- 2014/09/13 06:00
MHDA- 2014/09/13 06:01
PMCR- 2014/09/12
CRDT- 2014/09/13 06:00
PHST- 2014/07/07 00:00 [received]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2014/09/13 06:01 [medline]
PHST- 2014/09/12 00:00 [pmc-release]
AID - 62 [pii]
AID - 10.1007/s13555-014-0062-1 [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2014 Dec;4(2):233-48. doi: 10.1007/s13555-014-0062-1. 
      Epub 2014 Sep 12.